1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(18):3063-72.
2. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and metabolism clinics of North America. 2011;40(1):1-18, vii.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-59.
4. Frilling A, Akerström G, Falconi M, Pavel M, Ramos J, Kidd M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocrine-related cancer. 2012;19(5):R163-85.
5. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA oncology. 2017;3(10):1335-42.
6. Bertani E, Ravizza D, Milione M, Massironi S, Grana CM, Zerini D, et al. Neuroendocrine neoplasms of rectum: A management update. Cancer treatment reviews. 2018;66:45-55.
7. Stich V, Berlan M. Physiological regulation of NEFA availability: lipolysis pathway. Proc Nutr Soc. 2004;63(2):369-74.
8. Zhu B, Zhang J, Zheng Q, Dong B, Wang M, Liu J, et al. Free Fatty Acid is a Promising Biomarker in Triage Screening for Patients with Colorectal Cancer: A Case-Control Study. Cancer management and research. 2021;13:3749-59.
9. Zhang C, Liao Y, Liu P, Du Q, Liang Y, Ooi S, et al. FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism. Theranostics. 2020;10(15):6561-80.
10. Kawaguchi K, Senga S, Kubota C, Kawamura Y, Ke Y, Fujii H. High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells. FEBS Open Bio. 2016;6(3):190-9.
11. Ganjali S, Ricciuti B, Pirro M, Butler AE, Atkin SL, Banach M, et al. High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. Trends in endocrinology and metabolism: TEM. 2019;30(1):12-24.
12. Wang Y, Sun XQ, Lin HC, Wang DS, Wang ZQ, Shao Q, et al. Correlation between immune signature and high-density lipoprotein cholesterol level in stage II/III colorectal cancer. Cancer Med. 2019;8(3):1209-17.
13. Penson P, Long DL, Howard G, Howard VJ, Jones SR, Martin SS, et al. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular research. 2019;115(1):204-12.
14. Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):139-43.
15. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-12.
16. Ganjali S, Banach M, Pirro M, Fras Z, Sahebkar A. HDL and cancer - causality still needs to be confirmed? Update 2020. Seminars in cancer biology. 2021;73:169-77.
17. Pascual G, Domínguez D, Elosúa-Bayes M, Beckedorff F, Laudanna C, Bigas C, et al. Dietary palmitic acid promotes a prometastatic memory via Schwann cells. Nature. 2021.
18. Ghosh A, Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. Journal of biomedical science. 2017;24(1):50.
19. Su X, Peng D. The exchangeable apolipoproteins in lipid metabolism and obesity. Clinica chimica acta; international journal of clinical chemistry. 2020;503:128-35.
20. Raitakari OT, Mäkinen VP, McQueen MJ, Niemi J, Juonala M, Jauhiainen M, et al. Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. Atherosclerosis. 2013;226(1):245-51.
21. MacIntosh PW, Jakobiec FA, Stagner AM, Gilani S, Fay A. High grade neuroendocrine neoplasm of the antrum and orbit. Survey of ophthalmology. 2015;60(5):486-94.
22. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Annals of surgical oncology. 2010;17(9):2427-43.
23. Wiedenmann B. Synaptophysin. A widespread constituent of small neuroendocrine vesicles and a new tool in tumor diagnosis. Acta oncologica (Stockholm, Sweden). 1991;30(4):435-40.
24. Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, et al. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Archives of gerontology and geriatrics. 2009;48(2):213-7.
25. Warner RR, Curran T, Shafir MK, Schiano TD, Khaitova V, Kim MK. Serum and ascites chromogranin-A in patients with metastatic neuroendocrine tumors. Pancreas. 2011;40(4):622-6.
26. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018;68(6):471-87.
27. Qiu S, Pellino G, Warren OJ, Mills S, Goldin R, Kontovounisios C, et al. Mixed adenoneuroendocrine carcinoma of the colon and rectum. Acta chirurgica Belgica. 2018;118(5):273-7.
28. Ramage JK, Valle JW, Nieveen van Dijkum EJM, Sundin A, Pascher A, Couvelard A, et al. Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. Neuroendocrinology. 2019;108(1):45-53.
29. Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P, et al. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocrine-related cancer. 2018;25(5):583-93.